Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer

In total, 70 patients were enrolled into this phase II study, to evaluate the activity of the pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) combination in recurrent ovarian cancer patients. PLD, 30 mg m(−2), was administered on day 1 by 60′ i.v. infusion, followed by GEM, 1000 mg m(−2)...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: D'Agostino, G, Ferrandina, G, Ludovisi, M, Testa, A, Lorusso, D, Gbaguidi, N, Breda, E, Mancuso, S, Scambia, G
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2003
Konular:
Clinical
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2394291/
https://ncbi.nlm.nih.gov/pubmed/14520442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601284
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller